In further coverage of this week's announcement of supplementary data from our Phase 1 clinical trial of AMP945, Amplia's Chief Scientific Officer, Dr Mark Devlin, spoke with Andrew Scott from Proactive to discuss the significance of these data.
![](/site/file/15/ScreenShot20211130at4.26.12pm.png)
Watch the video.